Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial (Q34242939)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial (English)

1 reference

Europe PubMed Central

31 July 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maria Debiec-Rychter

13

object named as

Maria Debiec-Rychter

1 reference

Europe PubMed Central

31 July 2017

6

object named as

Raf Sciot

1 reference

Europe PubMed Central

31 July 2017

Frank Van Calenbergh

10

object named as

Frank Van Calenbergh

1 reference

Europe PubMed Central

31 July 2017

Stefaan Van Gool

2

object named as

Stefaan W Van Gool

1 reference

Europe PubMed Central

31 July 2017

5

object named as

Steffen Fieuws

1 reference

Europe PubMed Central

31 July 2017

Philippe Demaerel

8

object named as

Philippe Demaerel

1 reference

Europe PubMed Central

31 July 2017

author name string

Hilko Ardon

1

1 reference

Europe PubMed Central

31 July 2017

Tina Verschuere

3

1 reference

Europe PubMed Central

31 July 2017

Wim Maes

4

1 reference

Europe PubMed Central

31 July 2017

Guido Wilms

7

1 reference

Europe PubMed Central

31 July 2017

Jan Goffin

9

1 reference

Europe PubMed Central

31 July 2017

Johan Menten

11

1 reference

Europe PubMed Central

31 July 2017

Paul Clement

12

1 reference

Europe PubMed Central

31 July 2017

Steven De Vleeschouwer

14

1 reference

Europe PubMed Central

31 July 2017

publication date

22 April 2012

1 reference

Europe PubMed Central

31 July 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

31 July 2017

61

1 reference

Europe PubMed Central

31 July 2017

2033-2044

1 reference

Europe PubMed Central

31 July 2017

11

1 reference

Europe PubMed Central

31 July 2017

https://scigraph.springernature.com/pub.10.1007/s00262-012-1261-1

0 references

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Immunotherapy of diffuse gliomas: biological background, current status and future developments

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Dendritic cell therapy of high-grade gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Chemoimmunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Marrying immunotherapy with chemotherapy: why say IDO?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1261-1

21 January 2018

Identifiers

10.1007/S00262-012-1261-1

1 reference

Europe PubMed Central

31 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34242939&oldid=1971095165"